))
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
Manage episode 439790621 series 3381434
Контент предоставлен ReachMD. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией ReachMD или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
CME credits: 0.50
Valid until: 13-09-2025
Claim your CME credit at https://reachmd.com/programs/cme/targeting-resistance-in-egfrm-nsclc-with-her3-directed-adcs-in-the-community-setting/24489/
The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity. =
…
continue reading
Valid until: 13-09-2025
Claim your CME credit at https://reachmd.com/programs/cme/targeting-resistance-in-egfrm-nsclc-with-her3-directed-adcs-in-the-community-setting/24489/
The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity. =
484 эпизодов
Поделиться
